NCT01547598 - Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction | Biotech Hunter

Enrollment

135

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions

Glaucoma, Open-AngleOcular Hypertension

Interventions

DRUG

travoprost ophthalmic solution 0.004%

Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks.

DRUG

travoprost 0.004% / timolol 0.5% combination ophthalmic solution

DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.

DRUG

Bimatoprost ophthalmic solution 0.01%

LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.

Trial Locations (1)

Unknown

Vancouver